Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Children and Adolescents 6 to 17 Years of Age – Stocks News Feed
mRNA-1273.222 Targets the BA.4/BA.5 Strains of Omicron Variant Authorization Is Based Upon Clinical and Pre-Clinical Data for Moderna’s Bivalent Vaccine Candidates CAMBRIDGE, MA / ACCESSWIRE / October 12, 2022 /…